As the American Society for Clinical Oncology (ASCO) conference got underway on Friday, Samsung Bioepis revealed the results of a one-year follow-up study on SB3, its biosimilar alternative to Roche's (ROG: SIX) blockbuster breast and stomach cancer treatment Herceptin (trastuzumab).
The study, which followed patients with early or locally advanced breast cancer, found no statistically-significant difference in mortality between SB3 and its reference biologic.
“The additional one-year follow-up study demonstrates the long-term safety profile of SB3,” said Chul Kim, head of the clinical sciences division at Samsung Bioepis, a joint venture between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB) that was only formally founded in 2012.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze